Suraksha Diagnostic Limited has informed the Exchange about Transcript
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suraksha Diagnostic reported Q1 FY26 total income of ₹73.49 crore, up 18.83% YoY, with EBITDA of ₹24.66 crore (margin 33.97%) and PAT of ₹9.18 crore (margin 12.64%). The company added 8 new centers, taking the network to 58 centers. Management announced entry into genomic medicine via the acquisition of a 63% stake in Fetomat Wellness and the launch of Suraksha Genomics, Eastern India's first complete genomic lab, with ₹22 crore already invested and another ₹45 crore planned. Revenue and EBITDA margin guidance for FY26 stands at 15% and 34-35% respectively, with 15-18 new centers planned this year. New center losses of ₹3-4 crore impacted Q1 margins, but mature centers (>2 years) deliver 37% EBITDA margins. No debt is planned, with FY26 capex of ~₹70 crore funded through internal accruals.
Positive near-term outlook with steady revenue and margin growth, supported by genomic medicine expansion. Short-term margins may face pressure from new center losses, but long-term margin expansion is expected as centers mature. The genomic vertical adds a new high-growth avenue.